Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand patents have been granted for its CelGro collagen medical device platform for soft tissue regeneration applications.
The patents, titled 'Sutureless repair of soft tissue, are now granted in Australia, New Zealand, China and Japan, with further applications progressing in the US and EU. The patents are set to expire on 12 October 2035.
Orthocell managing director Paul Anderson said, “These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair. Sutureless or tensionless repair is of particular importance in the optimal repair of damaged nerves and is a key part of the repair process undertaken in the CelGro nerve regeneration clinical study. This comes at a perfect time for the Company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, EU and AUS.”
Sutureless repair of soft tissue refers to the method of repairing damaged soft tissue without the use of sutures.
The company said sutureless repair has the potential to greatly improve the efficiency and efficacy of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use or stitches.